MedPath

AI Model Predicts High Blood Pressure and Complications from ECGs

A new AI model developed by researchers at Imperial College London can predict the risk of high blood pressure and related complications using electrocardiogram (ECG) data. This technology, set for clinical trials with NHS patients, aims to enable earlier intervention and lifestyle changes to prevent hypertension and its serious consequences.

An artificial intelligence (AI) model has been developed to predict both the risk of high blood pressure and which patients may experience complications from it, using data from electrocardiograms (ECGs). This innovative approach, detailed in a study published in JAMA Cardiology, leverages large datasets of over one million ECGs to train the AI, enabling it to identify patients at risk of developing high blood pressure or related complications such as strokes and heart attacks.
Key Findings:
  • The AI model can identify patterns in ECG data that predict high blood pressure risk and potential complications.
  • Patients in the highest risk group have a four times higher chance of developing high blood pressure compared to those in the lowest risk group.
  • The system can also predict the likelihood of strokes, heart attacks, and mortality based on an AI-generated score, independent of other clinical risk factors.
Clinical Trials and Future Applications:
  • Clinical trials are scheduled to begin by mid-2025 at Imperial College Healthcare NHS Trust hospitals, aiming to evaluate the benefits of this AI model in real-world patient care.
  • The trials will involve patients from both outpatient clinics and inpatient medical wards, focusing on the potential for earlier intervention and treatment.
Expert Insights:
  • Dr. Arunashis Sau, the lead researcher, emphasizes the importance of early identification of at-risk patients to motivate lifestyle changes that could prevent high blood pressure.
  • Dr. Fu Siong Ng, senior author, highlights the credibility and reliability of the AI tool in predicting health risks and its potential to significantly improve patient outcomes through earlier intervention.
This AI-enhanced ECG technology represents a significant advancement in the early detection and management of high blood pressure, offering a promising tool for reducing the risk of serious cardiovascular events. The research was supported by the British Heart Foundation and the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), underscoring the collaborative effort to develop new diagnostics and treatments for patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Peerbridge Health Launches COR-INSIGHT Trial for AI-Enabled Cardiac and Cardiopulmonary Diagnostics

Peerbridge Health has initiated the COR-INSIGHT Trial to validate the capabilities of its Peerbridge Cor® ambulatory ECG wearables, aiming to revolutionize cardiovascular and cardiopulmonary monitoring with AI-driven, non-invasive technology.

NHS Trials AI System 'Aire-DM' for Early Type 2 Diabetes Detection

Two NHS hospital trusts in London are trialing an AI system, Aire-DM, to detect early warning signs of type 2 diabetes using ECG heart traces.
Early data suggests Aire-DM can predict diabetes risk with approximately 70% accuracy, which improves when combined with patient data like age and blood pressure.

FDA Clears AI Tool AutoChamber for Detecting Heart Disease Risk on Chest CT Scans

The FDA has cleared HeartLung Technologies' AutoChamber, an AI tool that identifies cardiovascular risk factors from standard chest CT scans, including those performed for lung cancer screening.
AutoChamber analyzes CT scans to evaluate the risk of heart failure, atrial fibrillation, and stroke, conditions often unreported in current CT scan analyses.

Study shows AI helps boost breast screening accuracy

A recent study has found that artificial intelligence (AI) can improve breast screening outcomes by supporting human readers, enhancing accuracy and efficiency, and reducing unnecessary recalls. The BRAIx project, utilizing Australian AI capability, demonstrated significant benefits including a reduction in workload for breast radiologists and the potential for AI to predict future breast cancer risk.

AI Model Improves Clinical Trial Approval Prediction by Quantifying Uncertainty

A new AI model developed by Stanford and Rensselaer enhances the prediction accuracy of clinical trial approvals by quantifying uncertainty.
The model integrates selective classification with the Hierarchical Interaction Network (HINT) to identify and withhold predictions for low-confidence trials.

Torasemide Shows Promise in Genetically-Targeted Hypertension Treatment

A new study reveals that torasemide, a loop diuretic, significantly reduces blood pressure in hypertension patients with a specific UMOD gene variant.
Patients with two copies of the UMOD gene variation experienced a 5% reduction in average blood pressure after 16 weeks of torasemide treatment.

AI and Behavioral Data to Predict Mental Health Treatment Outcomes in Young Adults

Mount Sinai and IBM Research are collaborating on the PREDiCTOR study to predict mental health treatment outcomes using AI and behavioral data.
The study will analyze clinical interviews, smartphone data, and cognitive testing to identify patterns indicative of treatment discontinuation and hospitalization.

Oxford Heartbeat Completes Patient Recruitment for AI-Powered PreSize Neurovascular Software Trial

Oxford Heartbeat has concluded patient recruitment for its clinical trial of PreSize Neurovascular, an AI-powered software designed to aid in neurovascular surgery.
The trial, funded by the UK's NIHR, is a multicenter, prospective study run by Imperial Clinical Trials Unit, involving 100 patients with cerebral aneurysms.

AI Algorithm Identifies Novel Risk Genes for Autoimmune Diseases, Potential Therapeutic Compounds

Researchers have developed an AI algorithm, EXPRESSO, to predict autoimmune disease risk by analyzing genetic data, potentially enabling earlier intervention.
EXPRESSO integrates single-cell expression quantitative trait loci data with 3D genomic and epigenetic information to identify cell-type-specific risk genes.

AI Shows Promise in Predicting and Personalizing Treatment for Type 1 Diabetes

A new article in Diabetologia highlights the potential of artificial intelligence (AI) in identifying and stratifying individuals at risk of type 1 diabetes.
AI can analyze extensive data repositories to refine screening strategies and enhance early detection and preventive care for type 1 diabetes.

Reference News

[1]
AI model can predict high blood pressure and related complications from ECGs
imperial.nhs.uk · Jan 3, 2025

An AI model predicts high blood pressure and complications from ECGs, aiding early intervention. Clinical trials at Impe...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy